<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492333</url>
  </required_header>
  <id_info>
    <org_study_id>AGA_GFD_in_IBS</org_study_id>
    <nct_id>NCT03492333</nct_id>
  </id_info>
  <brief_title>Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status</brief_title>
  <acronym>GFD_IBS</acronym>
  <official_title>The Role of Antigliadin Antibodies in Predicting the Beneficial Effect of Gluten Free Diet in Unselected IBS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and
      also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria).

      Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of
      response to GFD. However, this has not been tested in a prospective study in IBS patients.
      Identification of predictors of a symptomatic response to GFD within the IBS population would
      improve the clinical management of these patients.

      The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal
      symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to
      their antigliadin antibodies status.

      Additional purposes include investigating effects gluten free diet may have on other
      parameters:

        -  Improvement of mood

        -  Quality of life and general well-being

        -  Changes in gut microbiota
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2012</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervention GFD in IBS and HV(controls)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement on gastrointestinal symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease &gt;2 points IBS Birmingham score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of gastrointestinal transit</measure>
    <time_frame>4 weeks</time_frame>
    <description>(SHAPE 25-50 radiopaque markers)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement anxiety and/or depression</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease &gt;2 points Hospital anxiety and depression (HAD) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement somatization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease somatization scores (PHQ15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement quality of life and well-being</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease in the psychological general well-being (PGWB) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>4 weeks</time_frame>
    <description>changes in microbial composition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gluten free diet</intervention_name>
    <description>Gluten-free diet- Instructions provided by a dietitian</description>
    <arm_group_label>Gluten free diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  IBS diagnosis (Rome III)

          -  Willingness to participate

        Exclusion Criteria:

          -  history of any organic disease including celiac disease

          -  Immune deficiency

          -  Major abdominal surgery

          -  Use of immunosuppressants, glucocorticosteroids or opioids

          -  Use of antibiotics in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Premysl Bercik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Farncombe Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antigliadin, gluten free diet, transit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

